Related references
Note: Only part of the references are listed.Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses
Vincent Madelain et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials
Vincent Madelain et al.
CLINICAL PHARMACOKINETICS (2016)
Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea
Daouda Sissoko et al.
PLOS MEDICINE (2016)
Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever
Brian B. Gowen et al.
ANTIVIRAL RESEARCH (2015)
Ebola virus dynamics in mice treated with favipiravir
Vincent Madelain et al.
ANTIVIRAL RESEARCH (2015)
Favipiravir for children with Ebola
Naim Bouazza et al.
LANCET (2015)
Dose regimen of favipiravir for Ebola virus disease
France Mentre et al.
LANCET INFECTIOUS DISEASES (2015)
Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model
Lisa Oestereich et al.
ANTIVIRAL RESEARCH (2014)
Post-exposure efficacy of Oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model
Sophie J. Smither et al.
ANTIVIRAL RESEARCH (2014)
The Impact of Single Nucleotide Polymorphisms on Human Aldehyde Oxidase
Tobias Hartmann et al.
DRUG METABOLISM AND DISPOSITION (2012)
Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action
Caroline Bazzoli et al.
CLINICAL PHARMACOKINETICS (2010)
Pharmacokinetic changes in critical illness
Bradley A. Boucher et al.
CRITICAL CARE CLINICS (2006)
Viral hemorrhagic fevers
Aileen M. Marty et al.
CLINICS IN LABORATORY MEDICINE (2006)
Share Paper
